Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

What do we really know about the appropriateness of radiation emitting imaging for low back pain in primary and emergency care? A systematic review and meta-analysis of medical record reviews.

Logan GS, Pike A, Copsey B, Parfrey P, Etchegary H, Hall A.

PLoS One. 2019 Dec 5;14(12):e0225414. doi: 10.1371/journal.pone.0225414. eCollection 2019.

2.

The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects.

Yu Y, Carey M, Pollett W, Green J, Dicks E, Parfrey P, Yilmaz YE, Savas S.

BMC Med. 2019 Jul 29;17(1):150. doi: 10.1186/s12916-019-1379-5.

3.

Joint nested frailty models for clustered recurrent and terminal events: An application to colonoscopy screening visits and colorectal cancer risks in Lynch Syndrome families.

Choi YH, Jacqmin-Gadda H, Król A, Parfrey P, Briollais L, Rondeau V.

Stat Methods Med Res. 2019 Jul 26:962280219863076. doi: 10.1177/0962280219863076. [Epub ahead of print]

PMID:
31347460
4.

Correction to: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

BMC Cancer. 2019 May 10;19(1):437. doi: 10.1186/s12885-019-5672-7.

5.

Meta-analysis of 16 studies of the association of alcohol with colorectal cancer.

McNabb S, Harrison TA, Albanes D, Berndt SI, Brenner H, Caan BJ, Campbell PT, Cao Y, Chang-Claude J, Chan A, Chen Z, English DR, Giles GG, Giovannucci EL, Goodman PJ, Hayes RB, Hoffmeister M, Jacobs EJ, Joshi AD, Larsson SC, Le Marchand L, Li L, Lin Y, Männistö S, Milne RL, Nan H, Newton CC, Ogino S, Parfrey PS, Petersen PS, Potter JD, Schoen RE, Slattery ML, Su YR, Tangen CM, Tucker TC, Weinstein SJ, White E, Wolk A, Woods MO, Phipps AI, Peters U.

Int J Cancer. 2020 Feb 1;146(3):861-873. doi: 10.1002/ijc.32377. Epub 2019 Jun 7.

PMID:
31037736
6.

A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

BMC Cancer. 2019 Feb 9;19(1):133. doi: 10.1186/s12885-019-5346-5. Erratum in: BMC Cancer. 2019 May 10;19(1):437.

7.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
8.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
9.

Discovery of common and rare genetic risk variants for colorectal cancer.

Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK, Greenside P, Wainberg M, Schumacher FR, Smith JD, Levine DM, Nelson SC, Sinnott-Armstrong NA, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Bamia C, Banbury BL, Baron JA, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Chirlaque MD, Cho SH, Connolly CM, Cross AJ, Cuk K, Curtis KR, de la Chapelle A, Doheny KF, Duggan D, Easton DF, Elias SG, Elliott F, English DR, Feskens EJM, Figueiredo JC, Fischer R, FitzGerald LM, Forman D, Gala M, Gallinger S, Gauderman WJ, Giles GG, Gillanders E, Gong J, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hampel H, Harlid S, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Hunter DJ, Ibañez-Sanz G, Idos GE, Ingersoll R, Jackson RD, Jacobs EJ, Jenkins MA, Joshi AD, Joshu CE, Keku TO, Key TJ, Kim HR, Kobayashi E, Kolonel LN, Kooperberg C, Kühn T, Küry S, Kweon SS, Larsson SC, Laurie CA, Le Marchand L, Leal SM, Lee SC, Lejbkowicz F, Lemire M, Li CI, Li L, Lieb W, Lin Y, Lindblom A, Lindor NM, Ling H, Louie TL, Männistö S, Markowitz SD, Martín V, Masala G, McNeil CE, Melas M, Milne RL, Moreno L, Murphy N, Myte R, Naccarati A, Newcomb PA, Offit K, Ogino S, Onland-Moret NC, Pardini B, Parfrey PS, Pearlman R, Perduca V, Pharoah PDP, Pinchev M, Platz EA, Prentice RL, Pugh E, Raskin L, Rennert G, Rennert HS, Riboli E, Rodríguez-Barranco M, Romm J, Sakoda LC, Schafmayer C, Schoen RE, Seminara D, Shah M, Shelford T, Shin MH, Shulman K, Sieri S, Slattery ML, Southey MC, Stadler ZK, Stegmaier C, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Thomas SS, Toland AE, Trichopoulou A, Ulrich CM, Van Den Berg DJ, van Duijnhoven FJB, Van Guelpen B, van Kranen H, Vijai J, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Win AK, Wolf CR, Wolk A, Woods MO, Wu AH, Zaidi SH, Zanke BW, Zhang Q, Zheng W, Scacheri PC, Potter JD, Bassik MC, Kundaje A, Casey G, Moreno V, Abecasis GR, Nickerson DA, Gruber SB, Hsu L, Peters U.

Nat Genet. 2019 Jan;51(1):76-87. doi: 10.1038/s41588-018-0286-6. Epub 2018 Dec 3.

10.

Impact of colonoscopic screening in Familial Colorectal Cancer Type X.

Hatfield E, Green JS, Woods MO, Warden G, Parfrey PS.

Mol Genet Genomic Med. 2018 Nov;6(6):1021-1030. doi: 10.1002/mgg3.478. Epub 2018 Oct 9.

11.

Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.

Parfrey PS.

Kidney Int. 2018 Oct;94(4):661-662. doi: 10.1016/j.kint.2018.06.022.

PMID:
30243312
12.

Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

Biomark Res. 2018 Jun 13;6:17. doi: 10.1186/s40364-018-0133-z. eCollection 2018.

13.

Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer.

Yu Y, Cheng D, Parfrey P, Liu G, Savas S.

PLoS One. 2018 Jun 12;13(6):e0198873. doi: 10.1371/journal.pone.0198873. eCollection 2018.

14.

Hypothesis and data-driven dietary patterns and colorectal Cancer survival: findings from Newfoundland and Labrador colorectal Cancer cohort.

Sharma I, Roebothan B, Zhu Y, Woodrow J, Parfrey PS, Mclaughlin JR, Wang PP.

Nutr J. 2018 May 25;17(1):55. doi: 10.1186/s12937-018-0362-x.

15.

Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P.

Kidney Int. 2018 Jun;93(6):1475-1482. doi: 10.1016/j.kint.2017.12.014. Epub 2018 Mar 7.

PMID:
29525393
16.

Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Campbell PT, Li Y, Yang N, Zhou X, Dicks E, Mclaughlin JR, Parfrey PS.

BMC Cancer. 2018 Feb 6;18(1):155. doi: 10.1186/s12885-018-4026-1.

17.

XRCC3 Thr241Met and TYMS variable number tandem repeat polymorphisms are associated with time-to-metastasis in colorectal cancer.

He Y, Penney ME, Negandhi AA, Parfrey PS, Savas S, Yilmaz YE.

PLoS One. 2018 Feb 2;13(2):e0192316. doi: 10.1371/journal.pone.0192316. eCollection 2018.

18.

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V.

Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2.

PMID:
29392552
19.

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.

Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P.

Am J Nephrol. 2017;46(6):488-497. doi: 10.1159/000485326. Epub 2017 Dec 14.

20.

Inflammatory diet and risk for colorectal cancer: A population-based case-control study in Newfoundland, Canada.

Sharma I, Zhu Y, Woodrow JR, Mulay S, Parfrey PS, Mclaughlin JR, Hebert JR, Shivappa N, Li Y, Zhou X, Wang PP.

Nutrition. 2017 Oct;42:69-74. doi: 10.1016/j.nut.2017.05.010. Epub 2017 Jun 1.

PMID:
28870481
21.

Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Sharma I, Li Y, Zhou X, Yang N, Campbell PT, Dicks E, Parfrey PS, Mclaughlin JR.

Br J Cancer. 2017 Sep 5;117(6):898-906. doi: 10.1038/bjc.2017.242. Epub 2017 Aug 1.

22.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
23.

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.

Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, Smyth A, Rathe-Skafel A, Gao P, Mazzetti A, Bosch J, Yan AT, Parfrey P, Manns BJ, Walsh M.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):965-973. doi: 10.2215/CJN.10941016. Epub 2017 May 26.

24.

Germline INDELs and CNVs in a cohort of colorectal cancer patients: their characteristics, associations with relapse-free survival time, and potential time-varying effects on the risk of relapse.

Werdyani S, Yu Y, Skardasi G, Xu J, Shestopaloff K, Xu W, Dicks E, Green J, Parfrey P, Yilmaz YE, Savas S.

Cancer Med. 2017 Jun;6(6):1220-1232. doi: 10.1002/cam4.1074. Epub 2017 May 23.

25.

Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.

Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, Chertow GM, Parfrey P, Ma X, Floege J.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):315-322. doi: 10.2215/CJN.04720416. Epub 2016 Dec 9.

26.

Evaluation of a population-based approach to familial colorectal cancer.

Parfrey PS, Dicks E, Parfrey O, McNicholas PJ, Noseworthy H, Woods MO, Negriin C, Green J.

Clin Genet. 2017 May;91(5):672-682. doi: 10.1111/cge.12877. Epub 2017 Mar 8.

27.

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022. Epub 2016 Sep 16.

28.

No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients.

Dan LA, Werdyani S, Xu J, Shestopaloff K, Hyde A, Dicks E, Younghusband B, Green J, Parfrey P, Xu W, Savas S.

Cancer Med. 2016 Sep;5(9):2221-31. doi: 10.1002/cam4.796. Epub 2016 Jun 23.

29.

Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Sabe MA, Claggett B, Burdmann EA, Desai AS, Ivanovich P, Kewalramani R, Lewis EF, McMurray JJ, Olson KA, Parfrey P, Solomon SD, Pfeffer MA.

J Am Heart Assoc. 2016 Apr 23;5(4). pii: e002850. doi: 10.1161/JAHA.115.002850.

30.

The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.

Abdalla S, Montez-Rath ME, Parfrey PS, Chertow GM.

Contemp Clin Trials. 2016 May;48:119-24. doi: 10.1016/j.cct.2016.04.001. Epub 2016 Apr 11.

PMID:
27080930
31.

Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.

Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, Chertow GM, Belozeroff V.

Med Decis Making. 2016 Nov;36(8):965-72. doi: 10.1177/0272989X16638312. Epub 2016 Mar 17.

PMID:
26987347
32.

Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.

Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.

Circ Arrhythm Electrophysiol. 2016 Mar;9(3). pii: e003589. doi: 10.1161/CIRCEP.115.003589.

PMID:
26966288
33.

Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.

Savio AJ, Daftary D, Dicks E, Buchanan DD, Parfrey PS, Young JP, Weisenberger D, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B.

BMC Cancer. 2016 Feb 17;16:113. doi: 10.1186/s12885-016-2149-9.

34.

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH.

Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007. Epub 2015 Oct 9.

35.

Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability.

Zhai G, Zhou J, Woods MO, Green JS, Parfrey P, Rahman P, Green RC.

Eur J Hum Genet. 2016 Jul;24(7):1063-70. doi: 10.1038/ejhg.2015.256. Epub 2015 Dec 16.

36.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

37.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

38.

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, Levey AS, Ivanovich P, Eckardt KU, Kewalramani R, Toto R, Pfeffer MA.

Am Heart J. 2015 Aug;170(2):322-9. doi: 10.1016/j.ahj.2015.05.008. Epub 2015 May 22.

PMID:
26299230
39.

Mitochondrial DNA polymorphisms, its copy number change and outcome in colorectal cancer.

Mohideen AM, Dicks E, Parfrey P, Green R, Savas S.

BMC Res Notes. 2015 Jun 27;8:272. doi: 10.1186/s13104-015-1250-5.

40.

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.

Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM.

Pharm Stat. 2015 Jul-Aug;14(4):368. doi: 10.1002/pst.1694. Epub 2015 Jun 10. No abstract available.

PMID:
26096896
41.

A Survival Association Study of 102 Polymorphisms Previously Associated with Survival Outcomes in Colorectal Cancer.

Savas S, Xu J, Werdyani S, Shestopaloff K, Dicks E, Green J, Parfrey P, Green R, Xu W.

Biomed Res Int. 2015;2015:968743. doi: 10.1155/2015/968743. Epub 2015 May 12.

42.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
43.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438
44.

Psychometric properties of the Patient's Perception of Life on Hemodialysis Scale.

Twomey JC, Barrett BJ, Way CY, Churchill DN, Parfrey PS.

J Nurs Meas. 2015;23(1):72-81.

PMID:
25985496
45.

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS.

Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17.

46.

A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes.

Xu W, Xu J, Shestopaloff K, Dicks E, Green J, Parfrey P, Green R, Savas S.

Biomark Res. 2015 Mar 19;3:6. doi: 10.1186/s40364-015-0031-6. eCollection 2015.

47.

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.

Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM.

Pharm Stat. 2015 May-Jun;14(3):242-51. doi: 10.1002/pst.1680. Epub 2015 Apr 6. Erratum in: Pharm Stat. 2015 Jul-Aug;14(4):368.

PMID:
25851955
48.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

49.

Clinical genetic research 1: Bias.

Stuckless S, Parfrey PS.

Methods Mol Biol. 2015;1281:333-48. doi: 10.1007/978-1-4939-2428-8_20.

PMID:
25694320
50.

Randomized controlled trials: planning, monitoring, and execution.

Hatfield E, Dicks E, Parfrey PS.

Methods Mol Biol. 2015;1281:273-86. doi: 10.1007/978-1-4939-2428-8_16.

PMID:
25694316

Supplemental Content

Loading ...
Support Center